Ignazio Di Giovanna Ph.D., UK lead at PSNResearch



Ignazio has been in clinical research for over 30 years and is Head of Quality Assurance and First In-Man Trials for PSNResearch. He is co-editor of 'Principles of Clinical Research', past Chair of the Institute of Clinical Research and a member of the UK's Biotechnology & Pharmaceuticals Sector Advisory Group.

Ignazio has led a number of international clinical studies in neurological and neuromuscular diseases, supported by PSNResearch's highly experienced PMs and CRAs. The expertise of our teams ensures that each study is completed to the highest standards and that you can benefit from local know-how in the US and EU, coupled with international reach.

Rafael Zurita MSc, General Manager



Based in Spain, Rafael has 16 years experience in the health care sector; from information systems and health policy to hands-on clinical research, having previously worked in both pharma and CRO environments. He now drives our growth as an agile and adaptive clinical development company.

Please get in touch to find out how we can support your neurological or neuromuscular studies.

Dr. Ignazio Di Giovanna (UK) idigiovanna@psnresearch.com Tel: +44 (0) 1932 869933



www.PSNResearch.com



Local Knowledge | International Reach | Holistic Approach



www.PSNResearch.com

PSNResearch: The CRO for Agile and Emerging Biopharmas

PSNResearch is a full-service Clinical Research Organisation. We manage proof of concept, phase I to IV trials and Real World Evidence studies into drugs and therapies for small and medium sized biotech and pharma organisations.

We have proven expertise in managing studies for neurological and neuromuscular disorders including MND / ALS, Parkinson's, Huntingdon's and Alzheimer's, as well as research projects involving advanced, cell and gene therapy programmes for various disorders.

At **PSNResearch** we are committed to building a strong, effective rapport with sponsors and to developing lasting, mutually beneficial relationships with study sites and teams. This approach ensures the smooth running of even the most complex clinical development programmes.

Our unrivalled country knowledge in regulatory environments, and our commitment to becoming an integrated part of our clients' research teams, makes us the CRO of choice for a wide range of sponsors.

Our services include:

- Clinical trial monitoring from proof-of-concept to Phase IV and RWE
- Biostatistics and data management
- Investigator and patient recruitment
- Adaptive trial implementation
- Regulatory and development services
- Drug development advice and consultancy
- Drug supply services



Denmark • France • Germany • Italy • Netherlands • Spain • UK • USA

Why Choose PSNResearch?

PSNResearch was founded in 1997 with the ethos to deliver customised, personal CRO services which sets us apart from other clinical research organisations.

- Clinical expertise
- International framework
- Innovative processes
- Bespoke clinical trial solutions
- Local regulatory knowledge

At PSNResearch, we understand the science of success.

Case Studies: Multi-national ALS Research Projects

We managed multi-national studies conducted in up to six EU countries into respiratory and muscular parameters for the treatment of Motor Neurone Disease (ALS). The results of these studies are currently supporting further investigations for possible treatments of ALS.

This was what a US Sponsor said about our team:

"They recognize that ongoing clinical trials require attention 24/7 so they make themselves readily available. They are incredibly knowledgeable about the regulatory and various ethics requirements in Europe and we rely on their expertise in this area a great deal."

This was what a European Sponsor said about our team:

"They are really professional with good communication and training skills and have friendly and 'easy to cope with' relationships with the investigators and other study personnel. They keep all the stakeholders well informed of all study assessments and actions. They also understand various issues and challenges in ALS that may affect for example some efficacy assessments. It is very easy to co-operate with them and we as a study sponsor felt like we were one large team with PSN. Also our study sites were very happy with PSN's way of working."